Holding-brand versus operating-brand architecture for Zurich single and multi-family offices with US co-investment vehicles, portfolio-company US rollouts, or direct US platform-building. Swiss discretion carries standing in Paradeplatz. It does not travel to the American private banker, US family-office peer, or general partner reading the same materials in New York.
The family office has built standing in Zurich through the Paradeplatz-tier private-banking ecosystem, cantonal-grade governance, and quiet compounding across a generation of capital. The name carries among Swiss peers. Governance is clean. The portfolio performs. Then a US co-investment vehicle forms, a portfolio company rolls out in the United States, a US family-office peer requests a meeting, or an American general partner asks for materials. The gap surfaces in the first exchange.
US intermediaries, American private bankers, US family-office peers, and general partners, read Swiss discretion as category absence rather than depth. Holding-brand collateral built for a Zurich audience that already knows the name arrives on the desk of a New York reader who does not. The absence of a US category anchor, a US outcome claim, and a US peer set leaves the frame empty. The American fills the empty frame with Swiss stereotypes or with nothing at all, and the conversation loses momentum before the governance and thesis can carry weight.
The instinct is to produce more polished Paradeplatz-tier collateral or to fold the portfolio company further into the family narrative for credibility. Both instincts deepen the problem. What the US intermediary needs is two clear public layers that do different jobs, with the seam between them visible, and an operating brand that leads with a US category claim before Swiss origin sits as one supporting fact rather than the dominant one.
The US private banker is not evaluating the family. They are trying to locate the company. Swiss discretion and the holding-brand overflow have made that harder than it should be. House view on Zurich family-office positioning
The family office is not the problem. The portfolio is not the problem. The two surfaces are doing each other's job, and Swiss discretion is filling the frame the US category claim should have occupied.
Six to ten weeks. Single US category or single portfolio company. The firm rebuilds positioning, pricing posture, messaging, and trust architecture for the American co-investor, private banker, or US buyer, then launches it into market.
See the Sprint →Three to six months. Holding-brand and operating-brand surfaces rebuilt together, with the seam between them defined and visible. Typical when a US co-investment closes or a Zurich-held portfolio-company US rollout is imminent.
See the Build →Monthly retainer, twelve-month minimum. Ongoing rebuild-and-run across the holding brand and several portfolio-company surfaces. Standard shape for Zurich family offices with multiple US-facing brands or co-investment positions in play.
See the Partnership →No legal services. No Swiss company formation or US entity formation. No SFO or MFO structure design. No foundation, trust, or SPV setup. No FINMA licensing, EB-5, E-2, L-1, or O-1 visa work. No US tax structuring, FATCA analysis, CRS analysis, or double-tax-treaty review. No US banking introductions. No fiduciary services. No regulatory licensing. No IP filing. No contract drafting.
These belong with Swiss counsel who specialise in family-office structuring and US entry, and with US counsel on the American side. The firm works inside the parameters they set. When a marketing decision carries legal, tax, or fiduciary implications, the firm flags it and defers before execution.
The two brands do different jobs. The holding brand carries family standing, governance, and the long-arc capital thesis Zurich readers already know. The operating brand carries a US category, a US outcome claim, and a US peer set. When the two collapse into one surface, the US intermediary reads the portfolio company through the family-office prestige and Swiss origin together, and cannot locate the commercial category. The work is to build two distinct public layers, each passing the filter its audience uses, with the seam between them defined and visible.
Family-office-backed medtech, biotech, industrials, engineering-commercial holdings, and portfolio-company US commercialisation. The pattern is consistent across these sectors: the US category anchor is missing, the US peer set is absent, the holding brand bleeds into the operating brand, and Swiss understatement fills hero positions where US readers expect outcome claims. Fit is confirmed in discovery, not in published sector lists.
Yes. A common arrival route is a Zurich private-client lawyer, tax advisor, trust officer, or multi-family office introducing a principal whose holding structure is about to deploy capital into US co-investment or US platform-building. The fiduciary retains the principal relationship. The firm designs the US-facing commercial architecture inside the structure the fiduciary already manages. Fiduciary introductions route through partnerships@globalmarketing.agency.
Yes. The Zurich corridor covers Basel-adjacent biotech and medtech principals whose pipeline assets and IP are strong enough for US commercialisation but whose US-facing positioning does not yet land with US investors, KOLs, or payers. The work addresses the same register problem: academic-rigour bios, CHF-indexed track records, and Swiss understatement filling the hero where a US category claim and a US peer set belong.
With an inquiry through the contact form and a short discovery conversation. The firm runs three engagements: Market Entry Sprint (6 to 10 weeks), Cross-Border Build (3 to 6 months), or Group Partnership (monthly retainer, 12-month minimum). Fit and pricing are confirmed in discovery, not published. Family-office engagements most often begin as a Build or Partnership because the holding brand and several portfolio surfaces are typically in scope at once.
The wider Zurich entry gate for family offices, fiduciaries, and medtech, biotech, and engineering-commercial principals moving into the United States.
See the Zurich gate →Zurich private-client lawyers, tax advisors, trust officers, and family-office principals introducing international clients to US market engagements. Revenue-neutral, confidential, commission-free.
See fiduciaries in Zurich →Playbook for Zurich medtech and biotech principals carrying pipeline assets and IP into US commercialisation.
Read the piece →